Outlook Therapeutics Bolsa (NASDAQ: OTLK)

Últimas noticias sobre Outlook Therapeutics (NASDAQ:OTLK) Bolsa

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

Econ #s

NFIB Small Business Optimism (Jan) 102.8 vs 104.6 Est; 105.1 Prior

Guidance

SQNS

Sequans Expects Q1 Total Revenue Of $7M - $8M, Est $6.50M

General

Solidion's Silane-Free Silicon Anode Patents For High Energy Lithium-ion Batteries

MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116.67 percent. This is a 225 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $238.00 million which beat the analyst consensus estimate of $217.77 million by 9.29 percent. This is a 12.22 percent increase over sales of $212.08 million the same period last year.

MYTE

MYT Netherlands Parent Q2 Adj $0.13 Beats $0.06 Estimate, Sales $238.00M Beat $217.77M Estimate

Evercore ISI Group analyst Samir Khanal upgrades Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) from In-Line to Outperform and maintains the price target from $31 to $31.

Upgrades

Price Target

Analyst Ratings

Evercore ISI Group Upgrades Brixmor Property Group to Outperform, Maintains Price Target to $31

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3" rowspan="1">2025 Financial Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dollars in millions, unless noted</td>
<td colspan="1" rowspan="1">1Q'25E</td>
<td colspan="1" rowspan="1">Full Year 2025E</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales</td>
<td colspan="1" rowspan="1">~$3,025</td>
<td colspan="1" rowspan="1">$12,800 - $12,900</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating EBITDA(2)</td>
<td colspan="1" rowspan="1">~$760</td>
<td colspan="1" rowspan="1">$3,325 - $3,375</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS(2)</td>
<td colspan="1" rowspan="1">~$0.95</td>
<td colspan="1" rowspan="1">$4.30 - $4.40</td>
</tr>
</tbody>
</table>
</figure>

DuPont FY2025 Outlook: Adj EPS $4.30-$4.40 vs $4.34 Est; Sales $12.800B-$12.900B vs $12.92B Est

Leidos is initiating fiscal year 2025 guidance as specified in the table below.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Measure</td>
<td colspan="1" rowspan="1">FY25 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues (billions)</td>
<td colspan="1" rowspan="1">$16.9 - $17.3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin</td>
<td colspan="1" rowspan="1">Mid-High 12%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Diluted EPS</td>
<td colspan="1" rowspan="1">$10.35 - $10.75</td>
</tr>
</tbody>
</table>
</figure>

LDOS

Leidos Holdings Expects FY25 Revenue Of $16.9B-$17.3B Vs $16.98B Est, Adj EPS Of $10.35-$10.75 Vs $10.58 Est

DuPont Sees Q1 Adj EPS $0.95 vs $0.94 Est; Sees Sales $3.025B vs $3.05B Est

Nano Labs' AI Inference Device, YangTuo LLM Workstation Completes The Deployment Of DeepSeek.

Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. The company reported quarterly sales of $10.98 million which beat the analyst consensus estimate of $10.50 million by 4.57 percent. This is a 130.04 percent increase over sales of $4.77 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Sequans Communications Q4 2024 Adj EPADS $(0.08) Misses $(0.07) Estimate, Sales $10.98M Beat $10.50M Estimate

OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) reported quarterly sales of $66.81 million which beat the analyst consensus estimate of $65.39 million by 2.17 percent. This is a 18.72 percent increase over sales of $56.27 million the same period last year.

OrganiGram Holdings Q1 2025 Sales C$66.81M Beat C$65.39M Estimate, Net Loss Of C$22.96M Vs. C$15.75M YoY

WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) reported quarterly adjusted earnings of $3.16 per share which missed the analyst consensus estimate of $3.23 by 2.17 percent. This is a 19.25 percent increase over earnings of $2.65 per share from the same period last year. The company reported quarterly sales of $5.50 billion which beat the analyst consensus estimate of $5.41 billion by 1.68 percent. This is a 0.48 percent increase over sales of $5.47 billion the same period last year.

WESCO Intl Q4 Adj $3.16 Misses $3.23 Estimate, Sales $5.50B Beat $5.41B Estimate

DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $0.98 by 15.31 percent. This is a 29.89 percent increase over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $3.092 billion which beat the analyst consensus estimate of $3.068 billion by 0.80 percent. This is a 6.69 percent increase over sales of $2.898 billion the same period last year.

DuPont Q4 2024 Adj. EPS $1.13 Beats $0.98 Estimate, Sales $3.092B Beat $3.068B Estimate

ADEA

Adeia Renews Multi-Year Intellectual Property  License Agreement With Australia's Fetch TV

Leidos Holdings Q4 2024 Adj. EPS $2.37 Beats $2.27 Estimate, Sales $4.365B Beat $4.134B Estimate

BYDDY

HSAI

Hesai And BYD Partner To Provide Automotive Lidar For More Than 10 BYD Models

Shares of Chinese carmakers XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) and Geely Automobiles (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GELYF#OTC">GELYF</a>) fell on Tuesday after Chinese EV giant BYD Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) launched smart driving features on vehicles priced as low as $10,000.
What Happened: BYD on Monday rolled out an advanced driver-assist system called &#8220;God&#8217;s Eye&#8221; that it intends to install on a range of cars, including its low-cost Seagull hatchback priced under $10,000, for no added cost. The company began sales of 21 models equipped with the technology soon after the event.
BYD founder Wang Chuanfu said at the event that the company sees smart driving features becoming an essential part of cars like seatbelts or airbags.
The company also said that <a href="https://www.benzinga.com/markets/25/02/43614807/byd-teams-up-with-deepseek-to-outpace-tesla-in-budget-friendly-ai-driven-tech-for-chinese-cars-amid-regulatory-roadblocks">is integrating DeepSeek&#8217;s artificial intelligence</a> into at least the most advanced version of the new driver-assistance system.
Why It Matters: Driver assistance features are usually reserved for more premium EVs. Tesla, BYD&#8217;s American rival, also charges additionally for its driver assistance technology called Full self-driving (FSD) in the U.S. FSD, however, is <a href="https://www.benzinga.com/markets/equities/25/02/43615191/byds-gods-eye-and-huaweis-autonomous-driving-progress-spark-concerns-for-tesla-ross-gerber-points-out-all-use-lidar">not available in China.</a> 
Chinese EV startup Xpeng&#8217;s Hong Kong-listed shares are down 9% at HK$61.65. Its NYSE-listed shares also dropped 6.1% in pre-market trading in fear of heightened competition.
Xpeng offers advanced drive assistance features on its vehicles but not on vehicles as affordable as BYD&#8217;s Seagull hatchback. 
Hong Kong-listed shares of Geely Automobile also fell 10.3% to HK$15.9.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43615392/rivian-to-hike-r1t-r1s-prices-in-canada-by-nearly-10-from-feb-25-amid-exchange-rate-shift">Rivian To Hike R1T, R1S Prices In Canada By Nearly 10% From Feb 25 Amid Exchange Rate Shift</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

GELYF

XPEV

Xpeng, Geely Shares Fall After BYD Launches Advanced Driver Assistance Features On Car Priced Below $10,000

Shares of Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) rose sharply in pre-market trading after the company reported its fourth-quarter financial results after <a href="https://in.benzinga.com/25/02/43608715/lattice-semiconductor-shares-jump-after-mixed-q4-results-strong-q1-guidance">Monday&#8217;s closing bell</a>.
Lattice reported quarterly earnings of 15 cents per share, which missed the analyst consensus estimate of 19 cents. Quarterly revenue came in at $117.41 million, which beat the analyst consensus estimate of $117.09 million.&nbsp;
Lattice Semiconductor shares jumped 14.7% to $62.50 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Ocean Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) gained 86% to $0.2751 in pre-market trading. Ocean Biomedical shares gained 11% on Monday after the company announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) rose 63.5% to $1.12 in pre-market trading.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) gained 55.3% to $0.2869 in pre-market trading after jumping over 206% on Monday.</li>
<li>SelectQuote, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) gained 34.1% to $5.87 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY25 revenue guidance above estimates. Additionally, the company announced a $350 million strategic investment from several institutional investors.</li>
<li>Blue Hat Interactive Entertainment Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) shares jumped 28.4% to $0.0887 in pre-market trading after jumping 28% on Monday.</li>
<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) gained 24.8% to $2.86. LIXTE Biotechnology submitted request for withdrawal of Form S-1 registration statement.</li>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares climbed 22% to $0.5780 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) gained 16.8% to $1.53 in pre-market trading.</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) gained 6.6% to $131.87 in pre-market. Activist investor Elliott Investment Management has amassed a $2.5 billion stake in Phillips 66, significantly expanding its position in the U.S. oil refiner and intensifying pressure for operational restructuring, particularly regarding its midstream business.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) shares fell 35.1% to $8.48 in pre-market trading after the company reported worse-than-expected first-quarter financial results and issued FY25 revenue guidance below estimates.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) dipped 30.2% to $0.0891 in pre-market trading. Tantech Holdings announced a 1-for-40 common share consolidation.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) fell 25.6% to $8.27 in today's pre-market trading after the company issued first-quarter earnings and revenue guidance below estimates.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) shares fell 19.8% to $2.06 in pre-market trading. NLS Pharmaceutics shares jumped 37% on Monday after the company announced it will join forces with Kadimastem for diabetes treatment.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares tumbled 19.2% to $0.5599 in pre-market trading after jumping 70% on Monday.</li>
<li>Prelude Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) declined 16.4% to $0.9110 in pre-market trading after gaining 8% on Monday.</li>
<li>Surgery Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) fell 10.1% to $23.00 in pre-market trading.</li>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) fell 9.8% to $0.4780 in pre-market trading after gaining 4% on Monday.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) fell 9.5% to $22.04 in pre-market trading after the company missed fourth-quarter revenue estimates.</li>
<li>Axcelis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) shares dipped 8.3% to $62.00 in pre-market trading following fourth-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

Movers

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Piper Sandler analyst Christopher Raymond downgrades Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) from Overweight to Neutral and lowers the price target from $20 to $4.

Downgrades

QTTB

Piper Sandler Downgrades Q32 Bio to Neutral, Lowers Price Target to $4

Health Care

LIPO

Lipella Pharmaceuticals Shares Phase 2a Results For LP-310 In The Treatment Of Oral Lichen Planus, Showing Favorable Safety Profile And Tolerability Of Twice-Daily Oral Rinse

Outlook Therapeutics ( ($OTLK) ) has released its Q4 earnings. Here is a breakdown of the information Outlook Therapeutics presented to its investo...

Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics (OTLK) has disclosed a new risk, in the Supply Chain category. Outlook Therapeutics faces significant business risk due to its...

Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies

Outlook Therapeutics (OTLK) has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two clini...

Outlook Therapeutics' ONS-5010 shown to be non-inferior to Lucentis in wet AMD

Outlook falls 10% on ONS-5010 update, warrant inducements

Outlook Therapeutics (OTLK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao fr...

Positive Outlook for Outlook Therapeutics Driven by Promising ONS-5010 Data and Strategic Market Positioning

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of $...

Chardan Capital Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)

Outlook Therapeutics (OTLK) announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January 18-2...

Outlook Therapeutics announces presentation of data from NORSE EIGHT

Outlook Therapeutics (OTLK) announced Faisal Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Sukhtian wil...

Outlook Therapeutics appoints Sukhtian as Chairman of the board of directors

Outlook Therapeutics names Faisal Sukhtian as chair

Outlook Therapeutics ( ($OTLK) ) has provided an update. On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement wit...

Outlook Therapeutics Secures Funding and Board Restructures

RHHBY

Management

Press Releases

Outlook Therapeutics® Announces Executive Leadership Transition

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor "What This Means" Segment

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Comments

Outlook Therapeutics

Noticias

Últimas noticias sobre Outlook Therapeutics (NASDAQ:OTLK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL